Search research articles
Contact Us
Filters
Showing results (221-230 of 259) with videos related to
Page
of 26
Sort By:
Breast Cancer Research and Treatment
|
December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
International Journal of Molecular Sciences
|
February 23, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Frontiers in Immunology
|
June 5, 2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer
Soraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, et al.
Clinical Breast Cancer
|
June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study
Soraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober, Eileen Holmes, José Baselga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2021
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Matteo Lambertini, Eva Blondeaux, Marco Bruzzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart, Marion Procter, Debora Fumagalli, et al.
The Lancet. Oncology
|
August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 259) with videos related to
Sort By:
Page
of 26
Breast Cancer Research and Treatment
|
December 28, 2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Noam Ponde, Ian Bradbury, Matteo Lambertini, et al.
International Journal of Molecular Sciences
|
February 23, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Frontiers in Immunology
|
June 5, 2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer
Soraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, et al.
Clinical Breast Cancer
|
June 7, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study
Soraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Jens Huober, Eileen Holmes, José Baselga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2021
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Matteo Lambertini, Eva Blondeaux, Marco Bruzzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart, Marion Procter, Debora Fumagalli, et al.
The Lancet. Oncology
|
August 13, 2019
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Cristina Saura, Dominik Hlauschek, Mafalda Oliveira, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Paolo Nuciforo, John Townend, Martine J Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Page
of 26